[Vaccinovigilance: Reported adverse reactions of immunological veterinary medicinal products in 2018]. / Vaccinovigilance: Gemeldete unerwünschte Wirkungen immunologischer Tierarzneimittel im Jahr 2018.
Schweiz Arch Tierheilkd
; 161(5): 299-306, 2019 May.
Article
em De
| MEDLINE
| ID: mdl-31064736
ABSTRACT
INTRODUCTION:
The registration of adverse events after the use of immunological veterinary medicinal products (VMP) is the aim of the vaccinovigilance reporting system in Switzerland. Adverse events comprise suspected adverse reactions and lack of expected efficacy. Since the Institute of virology and immunology (IVI) is the competent authority for the regulation of immunological VMP in Switzerland, the reporting system is administrated by the IVI. In 2018, 162 reports concerning authorized immunological VMP were received. While most of the reports were submitted by the marketing authorization holders (79%), practicing veterinary surgeons contributed to the reporting system, too (18%). Five reports were submitted by private persons (3%). Dogs were mainly affected (43%) with several terrier breeds and chihuahuas being the most frequently reported dog breeds. Further reports were related to cats (16%), cattle (14%) and horses (14%). Recently, the numbers of reports concerning cats (+26) and horses (+23) have considerably increased after there had been clearly less reports concerning these species (11 and 5, respectively) in the previous year. Most of the reports were based on the application of combined vaccines against canine distemper, hepatitis, parvovirosis and parainfluenza with or without leptospirosis in dogs as well as cat flu and feline panleukopenia in cats. In 29.6% of the submitted cases, the causality assessment between the vaccination and the reaction described was evaluated probable.INTRODUCTION:
L'objectif du système de vaccinovigilance est d'identifier les effets indésirables pouvant survenir à la suite de l'utilisation de médicaments immunologiques pour animaux en Suisse. En plus des effets indésirables, le système couvre aussi les cas d'absence d'efficacité souhaitée. Comme l'institut de virologie et d'immunologie (IVI) est l'autorité compétente en matière des médicaments vétérinaires immunologiques, il est chargé de gérer le système d'annonces de vaccinovigilance. En 2018, 162 notifications ont été soumises concernant des médicaments vétérinaires immunologiques approuvés commercialement. Bien que la plupart des notifications aient été envoyées par les sociétés d'enregistrement (79%), les vétérinaires praticiens (18%) et les particuliers (3%) ont également contribué avec des annonces. Les effets indésirables concernaient principalement les chiens (43%), surtout les chihuahuas et les terriers. Les chiens furent suivis des chats (16%), des bovins (14%) et des chevaux (14%). Comparé aux années précédentes, il y a eu une nette augmentation des notifications concernant les chats (+26) et les chevaux (+23). La plupart des annonces concernait des vaccins combinés contre la maladie de Carré, l'hépatite, la parvovirose et la parainfluenza avec ou sans composants contre la leptospirose chez les chiens, ou des vaccins contre le coryza et la panleukopénie chez les chats. Dans 29.6% des cas, la relation entre la réaction et l'utilisation du vaccin a été jugée probable.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Sistema de Registros
/
Vacinação
/
Sistemas de Notificação de Reações Adversas a Medicamentos
/
Drogas Veterinárias
/
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos
Limite:
Animals
País/Região como assunto:
Europa
Idioma:
De
Revista:
Schweiz Arch Tierheilkd
Ano de publicação:
2019
Tipo de documento:
Article